F Cremonini, G Chiarioni… - Neurogastroenterology & …, 2011 - Wiley Online Library Chronic constipation (CC) is widely prevalent in the Western world, with a significant negative impact on quality of life, yet new and effective pharmacological and non-pharmacological treatment options have only recently emerged. The article by Tack and colleagues in the current ...
[PDF] from umm.ac.idM Pimentel, A Lembo, WD Chey… - … England Journal of …, 2011 - Mass Medical Soc In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an ... Cited by 53 - Related articles - All 10 versions
AJ Lembo, HA Schneier, SJ Shiff… - … England Journal of …, 2011 - Mass Medical Soc Anthony J. Lembo, MD, Harvey A. Schneier, MD, Steven J. Shiff, MD, Caroline B. Kurtz, Ph.D., James E. MacDougall, Ph.D., Xinwei D. Jia, Ph.D., James Z. Shao, MS, Bernard J. Lavins, MD, Mark G. Currie, Ph.D., Donald A. Fitch, MPH, Brenda I. Jeglinski, Paul Eng, ...
R Krause, I Zollner-Schwetz, T Valentin… - … England Journal of …, 2011 - Mass Medical Soc Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)1 on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the development of resistance was not investigated in TARGET 1 or TARGET 2 (ClinicalTrials.gov numbers, ... Related articles - All 2 versions
U Khan, J Mason, P Hungin, J Varma… - Gut, 2011 - gut.bmj.com Methods Patients with refractory neuropathic constipation were offered temporary SNS (TSNS).Bilateral TSNS was performed under sedation and electrodes placed in the sacral foramen that produced the best peripheral response. The electrodes were removed after a 3 week ...
F Cremonini, G Chiarioni… - Neurogastroenterology & …, 2011 - Wiley Online Library Chronic constipation (CC) is widely prevalent in the Western world, with a significant negative impact on quality of life, yet new and effective pharmacological and non-pharmacological treatment options have only recently emerged. The article by Tack and colleagues in the current ...
[PDF] from umm.ac.idM Pimentel, A Lembo, WD Chey… - … England Journal of …, 2011 - Mass Medical Soc In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an ... Cited by 53 - Related articles - All 10 versions
AJ Lembo, HA Schneier, SJ Shiff… - … England Journal of …, 2011 - Mass Medical Soc Anthony J. Lembo, MD, Harvey A. Schneier, MD, Steven J. Shiff, MD, Caroline B. Kurtz, Ph.D., James E. MacDougall, Ph.D., Xinwei D. Jia, Ph.D., James Z. Shao, MS, Bernard J. Lavins, MD, Mark G. Currie, Ph.D., Donald A. Fitch, MPH, Brenda I. Jeglinski, Paul Eng, ...
R Krause, I Zollner-Schwetz, T Valentin… - … England Journal of …, 2011 - Mass Medical Soc Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)1 on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the development of resistance was not investigated in TARGET 1 or TARGET 2 (ClinicalTrials.gov numbers, ... Related articles - All 2 versions
U Khan, J Mason, P Hungin, J Varma… - Gut, 2011 - gut.bmj.com Methods Patients with refractory neuropathic constipation were offered temporary SNS (TSNS).Bilateral TSNS was performed under sedation and electrodes placed in the sacral foramen that produced the best peripheral response. The electrodes were removed after a 3 week ...